trending Market Intelligence /marketintelligence/en/news-insights/trending/v7oXnVwvkl-lM9ITDobdjQ2 content esgSubNav
In This List

Ono Pharmaceutical secures rights to 2 Array BioPharma cancer compounds

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Ono Pharmaceutical secures rights to 2 Array BioPharma cancer compounds

Ono Pharmaceutical Co. Ltd. secured the rights to two late-stage cancer compounds developed by Array BioPharma Inc.

The Japanese pharmaceutical company will pay $31.6 million for the rights to binimetinib and encorafenib in Japan and South Korea. The drugs are meant to treat BRAF-mutant melanoma and BRAF-mutant colorectal cancer.

Array BioPharma can receive up to an additional $156 million in milestone-related payments; it will also receive royalties on the sales of the drugs, which are in phase 3 trials and have yet to be approved in any country.

Ono may also conduct binimetinib and encorafenib clinical trials in both countries, in addition to contributing 12% of the costs in future global development.